Novartis/Human Genome Sciences Launch Second Phase III Albuferon Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan 2009 regulatory filings for the hepatitis C treatment.
You may also be interested in...
Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion
HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.
Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion
HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.
Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program
Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.